Seeking Alpha

WuXi PharmaTech inks licensing agreement with Mayo Clinic for PDX models

  • WuXi PharmaTech (WX +0.6%) announces a licensing agreement with Mayo Clinic's Center for Individualized Medicine.
  • The deal gives WX an exclusive license to a "panel of patient-derived xenograft [mouse] models for prevailing cancers in Western countries."
  • Ultimately, the goal here is to give WX a more extensive portfolio of models so that the company's customers can "select highly relevant models with a higher probability of success for testing targeted therapies." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)